A systematic review of economic evaluation literature in Thailand: Are the data good enough to be used by policy-makers?

PharmacoEconomics

Volumn 25, Issue 6, 2007, Pages 467-479

  Teerawattananon, Yot ^a   Russell, Steve ^b   Mugford, Miranda ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DISEASE CONTROL; ECONOMIC ASPECT; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THAILAND;

COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; ECONOMICS, PHARMACEUTICAL; PHARMACEUTICAL PREPARATIONS; THAILAND;

EID: 34249790590     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725060-00003     Document Type: Review

References (26)

1. Doherty J, Kamae I, Lee KKC, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health 2004; 7 (2): 118-32
2. Tangcharoesnathien V, Srithamrongswat S, Pittayarangsarit S. Overview of health insurance systems. In: Thammathataree J, editor. Health insurance systems in Thailand. Bangkok: Desire Publisher; 2001: 28-37
3. Teerawattananon Y, Tangcharoensathien V. Designing a reproductive health services package in the universal health insurance scheme in Thailand: match and mismatch of need, demand and supply. Health Policy Plan 2004; 19 Suppl. 1: i31-i9
4. Pannarunothai S, Patmasiriwat D, Srithamrongsawat S. Universal health coverage in Thailand: ideas for reform and policy struggling. Health Policy 2004; 68 (1): 17-30
5. Hoffmann C. The influence of economic evaluation studies on decision making: a european survey. Health Policy 2000; 52 (3): 179-92
6. Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007; 10 (1): 61-72
7. Stolk EA, Brouwer WB, Busschbach JJ. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. Health Policy 2002; 59 (1): 53-63
8. Walker D, Fox-Rushby J. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9: 681-98
9. Lee KS, Brouwer WB, Lee SI, et al. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations. Pharmacoeconomics 2005; 23 (7): 709-21
10. O'Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Manag Care 1997; 3 Suppl.: S33-9
11. Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond M, McGuire A, editors. Economic evaluation in health care. Oxford: Oxford University Press, 2001: 256-76
12. Teerawattananon Y, Mugford M. Is it worth offering a routine laparoscopic cholecystectomy in developing countries? A Thailand case study. Cost Eff Resour Alloc 2005; 3 (1): 10
13. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83
14. Drummond M, Sculpher M, Torrance G, et al. Method for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
15. Cooper N, Coyle D, Abrams K, et al. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 2005 Oct; 10 (4): 245-50
16. Bundhamcharoen K, Teerawattananon Y, Theo V, et al. Burden of disease and injuries in Thailand: priority setting for policy. The Thai Working Group on Burden of Disease and Injuries. Bangkok: Printing House of the War Veterans Organization of Thailand, 2002 [online]. Available at URL: http://203.157.19. 191/BURDEN.pdf [Accessed 14 Sep 2006]
17. Murray C, Lopez A. The global burden of diseases: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, WHO and World Bank, 1996
18. Neumann PJ, Rosen AB, Greenberg D, et al. Can we better prioritize resources for cost-utility research? Med Decis Making 2005; 25 (4): 429-36
19. Oliver A. Health economic evaluation in Japan: a case study of one aspect of health technology assessment. Health Policy 2003; 63 (2): 197-204
20. Neumann P. Using cost-effectiveness analysis to improve health care: opportunities and barriers. Oxford: Oxford University Press, 2005
21. Coast J. Is economic evaluation in touch with society's health values? BMJ 2004; 329 (7476): 1233-6
22. Tan-Torres E, Baltussen R, Adum T, et al. Making CHOICES in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003
23. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005; 43 (7 Suppl.): 5-14
24. Wiwanitkit V. Comparison of cost effectiveness between measuring the serum erythropoietin level and reticulocyte count for monitoring thalassemic patients: a note in Thai beta thalassemia/HbE subjects. Hematology 2004; 9 (4): 311-3
25. Cairns J. Discounting in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001
26. World Health Organization. The world health report 2002: reducing risks, promoting healthy life. Geneva: World Health Organization, 2002